lonafarnib has been researched along with Lung Neoplasms in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (92.86) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adema, AD; Honeywell, RJ; Peters, GJ; van der Born, K | 1 |
| Le Moulec, S; Loriot, Y; Soria, JC | 1 |
| Li, M; Liu, A; Liu, B; Luo, X; Yu, H; Zheng, H | 1 |
| Baum, C; Hollywood, E; Ilson, D; Kelsen, DP; Kemeny, N; O'Reilly, E; Saltz, LB; Sharma, S; Statkevich, P; Zaknoen, S; Zhu, Y | 1 |
| Ardizzoni, A; De Cupis, A; Favoni, RE; Loprevite, M; Mazzanti, P; Scolaro, T; Semino, C | 1 |
| Fu, H; Khuri, FR; Sun, SY; Wang, R; Zhou, Z | 1 |
| Chang, YS; Chun, KH; Hassan, K; Hong, WK; Ji, L; Khuri, FR; Lee, HY; Lotan, R; Moon, H | 1 |
| Bernhard, EJ | 1 |
| El-Naggar, A; Giannakakou, P; Hamel, E; Khuri, FR; Marcus, AI; Nivens, M; O'Brate, A; Wong, J; Yao, TP; Zhou, J | 1 |
| Fossella, FV; Glisson, BS; Khuri, FR; Kies, MS; Kim, ES; Munden, RF; Papadimitrakopoulou, V; Pisters, KM; Rogatko, A; Statkevich, P; Summey, C; Tighiouart, M; Zaknoen, S | 1 |
| Han, JY; Hong, WK; Kim, E; Lee, HY; Morgillo, F; Myers, JN; Oh, SH | 1 |
| Lee, HY; Morgillo, F | 1 |
| Khuri, FR; Liu, X; Marcus, AI; Sun, SY; Yue, P; Zou, W | 1 |
| Jin, Q; Khuri, FR; Kim, ES; Lee, HY; Oh, SH | 1 |
1 review(s) available for lonafarnib and Lung Neoplasms
| Article | Year |
|---|---|
Lonafarnib in cancer therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Leukemia; Lung Neoplasms; Piperidines; Pyridines; Randomized Controlled Trials as Topic | 2006 |
2 trial(s) available for lonafarnib and Lung Neoplasms
| Article | Year |
|---|---|
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biopsy, Needle; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperidines; Pyridines; Survival Analysis; Treatment Outcome | 2002 |
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Piperidines; Pyridines; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2005 |
11 other study(ies) available for lonafarnib and Lung Neoplasms
| Article | Year |
|---|---|
Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dacarbazine; Deoxycytidine; Deoxyguanosine; DNA Adducts; DNA Methylation; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Piperidines; Pyridines; Temozolomide | 2009 |
[Targeting KRAS pathway in NSCLC therapy].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Farnesyltranstransferase; Genes, ras; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Quinolones; raf Kinases; ras Proteins; Sorafenib | 2009 |
Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Monomeric GTP-Binding Proteins; Multiprotein Complexes; Mutation; Neuropeptides; Phosphorylation; Piperidines; Prenylation; Proteins; Pyridines; Quinolones; Ras Homolog Enriched in Brain Protein; Ribosomal Protein S6; RNA Interference; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Transfection | 2010 |
In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
Topics: Alkyl and Aryl Transferases; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lung Neoplasms; Piperidines; Pyridines | 2004 |
The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
Topics: Alkyl and Aryl Transferases; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cattle; Cell Cycle; Down-Regulation; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Serum Albumin, Bovine; Signal Transduction; Tumor Cells, Cultured | 2004 |
Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Topics: Adenoviridae; Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Flow Cytometry; Gene Expression Regulation, Neoplastic; Gene Products, tat; Genes, ras; Genetic Vectors; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; MAP Kinase Kinase 1; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Piperidines; Precipitin Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; ras Proteins; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Farnesyltransferase inhibition: who are the Aktors?
Topics: Alkyl and Aryl Transferases; Apoptosis; Cell Cycle; Down-Regulation; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction | 2004 |
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Topics: Acetylation; Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Drug Synergism; Farnesyltranstransferase; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Mice; Microtubules; Mitosis; NIH 3T3 Cells; Paclitaxel; Piperidines; Pyridines; Tubulin | 2005 |
Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Immunoprecipitation; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Piperidines; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Ubiquitin; Up-Regulation; Vascular Endothelial Growth Factor A | 2005 |
The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
Topics: Apoptosis; Caspase 8; Cell Line, Tumor; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Membrane Proteins; Piperidines; Pyridines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor CHOP; Up-Regulation | 2007 |
Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperidines; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survivin; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2008 |